Pharma channel feed

Pelosi threat­ens to slide drug pric­ing re­form in­to Biden's bud­get bill, re­jects in­dus­try push­back that in­no­va­tion would suf­fer

4 years ago

Ovid shuf­fles C-suite, lays off staff in wake of PhI­II An­gel­man syn­drome fail

4 years ago
People
R&D

Bio­gen nar­rows its Aduhelm la­bel af­ter FDA left the flood­gates open

4 years ago
FDA+

FDA shoots down pe­ti­tion to stall gener­ic ver­sions of Bris­tol My­er­s' block­buster chemo Abrax­ane

4 years ago
FDA+

Rep. Porter calls on HHS in­spec­tor gen­er­al to in­ves­ti­gate FDA-Bio­gen ties pri­or to Aduhelm's ap­proval

4 years ago
FDA+

If you thought the FDA’s ap­proval of Aduhelm for Alzheimer’s was con­tro­ver­sial, you should hear the ex­pert­s' thoughts on off-la­bel use

4 years ago

Eli Lil­ly, Boehringer In­gel­heim tout piv­otal heart fail­ure win for Jar­diance, po­ten­tial­ly set­ting up a No­var­tis show­down

4 years ago
R&D

Duke to host pri­vate meet­ing with pay­ers and bio­phar­ma on how to pay for Alzheimer's drugs

4 years ago
R&D
FDA+

Phar­ma in the crosshairs: How the FTC is ex­pand­ing its an­titrust pow­ers un­der its new chair

4 years ago

Roche reach­es out once again for the bud­get ax with plans to chop up to 400 de­vel­op­ment jobs in R&D

4 years ago
R&D

ICER finds Bio­gen’s new ex­or­bi­tant­ly priced Alzheimer’s drug doesn’t match even an op­ti­mistic view of po­ten­tial clin­i­cal ben­e­fits

4 years ago

Pa­tient ex­pe­ri­ence da­ta in reg­u­la­to­ry de­ci­sions: Ques­tions abound in first FDA re­port

4 years ago
FDA+

Ab­b­Vie says Rin­voq shines again as main­te­nance ther­a­py for ul­cer­a­tive col­i­tis — but safe­ty con­cerns still loom over JAK class

4 years ago
R&D

Gilead­'s Kite earns sec­ond-line win for CAR-T Yescar­ta, set­ting up a bat­tle over ear­li­er blood can­cer pa­tients

4 years ago
R&D
Cell/Gene Tx

Mul­ti­va­lent mR­NA vac­cines, I/O 3.0, long-act­ing HIV drugs: The $46B game is on for the new Glax­o­SmithK­line

4 years ago

A Pfiz­er win in a heat­ed an­ti-kick­back case could lead to a ‘gold rush’ of bio­phar­ma com­pa­nies sub­si­diz­ing Medicare drugs, gov­ern­ment says

4 years ago

Top an­a­lyst chimes in on bub­bling de­bate about Glax­o­SmithK­line's fu­ture with a clear mes­sage: Let your £40B vac­cines group go

4 years ago

Top Wyden pri­or­i­ty for drug price re­forms: Medicare ne­go­ti­a­tions

4 years ago

Mer­ck­'s Keytru­da blazes a path in first-line cer­vi­cal can­cer, mak­ing good on drug­mak­er's push for ear­li­er pa­tients

4 years ago
R&D

Bio­gen's new Alzheimer's drug serves as a ral­ly­ing cry for drug pric­ing re­forms

4 years ago
FDA+

Ac­tivist in­vestor El­liott in talks with oth­er Glax­o­SmithK­line in­vestors about re­plac­ing Em­ma Walm­s­ley, spin­ning off vac­cine busi­ness — re­port

4 years ago
People

HHS backs down in le­gal fight over drug dis­count pro­gram with As­traZeneca, Eli Lil­ly, No­vo and Sanofi

4 years ago

FDA's con­tro­ver­sial Aduhelm de­ci­sion leaves ALS pa­tients feel­ing spurned

4 years ago
In Focus

As drug­mak­ers spend $6B an­nu­al­ly on DTC ads, sen­a­tors re­vive bill to in­clude list prices in ads

4 years ago
First page Previous page 237238239240241242243 Next page Last page
A service from the Financial Times